Quote:

---

Sorry it took a minute to look up a little evidence of those who LL, as a CCR5 cannot help, or maybe in less similar ways is approximately 1% of total N in new populations, and up to 20-30% of Europeans that have descended from those that survived the Black Death.

---

The CCR5 delta 32 variation can be up to 20% in Europeans but this includes the single and double allele versions. A single allele version denotes a deletion of one of the pair of genes, a double allele means a deletion of both. Only 1% of Europeans have a deletion of both alleles.

In the single allele version you will see expression of CCR5 but at less frequency as shown by HIV reproduction and a slower progression to AIDS if left untreated. Even with a single allele, leronlimab could be of use but generally to a lesser extent.

We know Cytodyn tests for the existence of CCR5 expression in trials and the lack of it and would exclude someone. But single allele CCR5 delta 32 deletion would still express CCR5. This reduced effectiveness of leronlimab with the single allele may be a part of the reason for less responsiveness during treatment.